Immunoglobulins Market to 2017

Sept. 22, 2011 - PRLog -- The immunoglobulins market is a steadily growing market and it is expected to grow steadily in the forecast period without any significant thrust due to a weak pipeline with few innovations. The existing promising immunoglobulins are undergoing life-cycle management, with them being approved for new indications.

CSL’s Privigen, an approved intravenous immunoglobulin (IVIG) for PID is undergoing Phase III trials for approval as an immunomodulating therapy for CIDP in Europe. Similarly, Baxter’s Gammagard Liquid, an approved IVIG for the treatment of PID may seek approval for MMN in the recent future due to its favorable results in clinical studies. Immune-mediated neurological disorders are expected to be one of the biggest drivers of IVIG to 2017, driven by anticipated approvals for the treatment of MMN and other diseases such as Alzheimer's diseases. Moreover, further research and development (R&D) in immunoglobulins therapy is focused on the subcutaneous mode of administration of immunoglobulins, an area that commands significant interest in the treatment of PID.

For Sample Pages, please click or add the below link to your browser:
http://www.gbiresearch.com/RequestSamplePages.aspx?ID=Imm...

GBI Research’s report, “Immunoglobulins Market to 2017 - Off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth” provides in-depth analysis of the, drivers and barriers that affect the global immunoglobulins market. The report analyzes the markets for immunoglobulins products in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Epidemiology, revenue, and annual cost of therapy are forecast until 2017 for the key geographies as well as seven key therapeutic segments. The report also provides profiles for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

GBI Research has found that the global immunoglobulins market is a niche market in the
pharmaceutical industry. The indications covered in the study such as primary immunodeficiency (PID), Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis; multifocal motor neuropathy (MMN) and idiopathic thrombocytopenic purpura (ITP) have very low prevalence and incidence rates. Chronic lymphocytic leukemia (CLL), an indication covered in the report, has a high incidence rate compared to the other indications which are orphan diseases. The use of immunoglobulins as a mode of therapy differs from indication to indication. It has established therapeutic significance in the indications covered in the report. However, there is a significantly long list of indications where immunoglobulins are used off-label and as an alternative treatment when all the other established treatments fail to show any results. The expected growth in the overall market for immunoglobulins is due to reasons such as improved diagnosis of diseases and increasing number of patients as awareness about diseases increases; new indications where immunoglobulins are used; increased off-label uses; and the significantly high per-capita usage in the US. The market for immunoglobulins in the indications covered in the report has witnessed stable growth between 2002 and 2010. The market revenue in the forecast
period is expected to grow at a steady rate as there are very few promising pipeline immunoglobulins products. Moreover, the absence of generics leads to relatively weak competition in the market, compared to other therapeutic classes of drugs.

For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Immunoglobulins...

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.